决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers.
CAR-T 细胞(CAR T细胞)对血液系统恶性肿瘤有效。
CAR-T 细胞(CAR T细胞)对血液系统恶性肿瘤有效。然而,在实体瘤中,其效力受到局部免疫抑制以及CAR所靶向抗原异质性表达的限制。在此,我们展示表达来自幽门螺杆菌的多能促炎中性粒细胞激活蛋白(NAP)的CAR T细胞能够触发针对实体癌的内源性旁观者T细胞应答。在皮下小鼠胰腺导管腺癌、神经母细胞瘤或结肠癌小鼠中,CAR(NAP) T细胞相比常规小鼠CAR T细胞导致肿瘤生长更慢、生存率更高,且与靶抗原、肿瘤类型和宿主单倍型无关。在抗原异质性表达的肿瘤中,NAP分泌诱导形成免疫学“热”微环境,支持树突状细胞成熟和旁观者应答,表现为表位扩展以及靶向除CAR靶向抗原之外的其他肿瘤相关抗原的细胞毒性CD8+ T细胞浸润。装载NAP的CAR T细胞既未增加脱靶毒性,也未损害CAR T细胞的效力,因此可能具有有利的转化潜力。
Chimeric antigen receptor T cells (CAR T cells) are effective against haematologic malignancies. However, in solid tumours, their potency is hampered by local immunosuppression and by the heterogeneous expression of the antigen that the CAR targets. Here we show that CAR T cells expressing a pluripotent pro-inflammatory neutrophil-activating protein (NAP) from Helicobacter pylori trigger endogenous bystander T-cell responses against solid cancers. In mice with subcutaneous murine pancreatic ductal adenocarcinomas, neuroblastomas or colon carcinomas, CAR(NAP) T cells led to slower tumour growth and higher survival rates than conventional mouse CAR T cells, regardless of target antigen, tumour type and host haplotype. In tumours with heterogeneous antigen expression, NAP secretion induced the formation of an immunologically 'hot' microenvironment that supported dendritic cell maturation and bystander responses, as indicated by epitope spreading and infiltration of cytotoxic CD8 + T cells targeting tumour-associated antigens other than the CAR-targeted antigen. CAR T cells armed with NAP neither increased off-tumour toxicity nor hampered the efficacy of CAR T cells, and hence may have advantageous translational potential.
MEMBER ACCOUNT
登录成功会直接打开下一页。